CompletedPHASE1, PHASE2NCT00392951
Sirolimus for Autoimmune Disease of Blood Cells
Studying Idiopathic aplastic anemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Hospital of Philadelphia
- Principal Investigator
- David T. Teachey, MDChildren's Hospital of Philadelphia
- Intervention
- sirolimus(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 1-30 years · All sexes
- Timeline
- 2006 – 2016
Study locations (1)
- Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00392951 on ClinicalTrials.govOther trials for Idiopathic aplastic anemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05998408JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow FailureNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE2NCT05126849Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide in Patients With Acquired Refractory Aplastic Anemia or in Relapse After ImmunosuppressionAssistance Publique - Hôpitaux de Paris
- RECRUITINGNANCT05012111Natural History of Acquired and Inherited Bone Marrow Failure SyndromesNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE1, PHASE2NCT03500731Lung and Bone Marrow Transplantation for Lung and Bone Marrow FailurePaul Szabolcs